Home Cart Sign in  
Chemical Structure| 1214377-42-0 Chemical Structure| 1214377-42-0

Structure of 1214377-42-0

Chemical Structure| 1214377-42-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1214377-42-0 ]

CAS No. :1214377-42-0
Formula : C7H5BrF3NO
M.W : 256.02
SMILES Code : BrC1=CN=C(C(=C1)C(F)(F)F)OC
MDL No. :MFCD13185815
InChI Key :ZIOFHXRZJCIBCO-UHFFFAOYSA-N
Pubchem ID :53393182

Safety of [ 1214377-42-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1214377-42-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.29
Num. rotatable bonds 2
Num. H-bond acceptors 5.0
Num. H-bond donors 0.0
Molar Refractivity 43.43
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

22.12 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.35
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.73
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

4.02
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.38
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.05
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.91

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.36
Solubility 0.113 mg/ml ; 0.00044 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.85
Solubility 0.363 mg/ml ; 0.00142 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.9
Solubility 0.0326 mg/ml ; 0.000127 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.92 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.08

Application In Synthesis of [ 1214377-42-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1214377-42-0 ]

[ 1214377-42-0 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 121643-44-5 ]
  • [ 1214377-42-0 ]
YieldReaction ConditionsOperation in experiment
74% Intermediate 1 : 5-Bromo-<strong>[121643-44-5]2-methoxy-3-trifluoromethyl-pyridine</strong> To <strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> (20.0 g, 1 13.0 mmol) and 1 ,3-dibromo-5,5- dimethylimidazolidine-2,4-dione (43.6 g, 152.0 mmol) was added TFA (80 mL) and the resulting mixture stirred at rt for 18h under argon. The TFA was removed in vacuo (50 mbar, 45C) and the residue suspended in tert-butyl methyl ether (200 mL). The resulting colourless solid was removed by filtration and washed with tert-butyl methyl ether (50 mL). The filtrate was concentrated in vacuo and suspended in EtOAc (50 mL) The insoluble colourless solid was removed by filtration and washed with EtOAc (50 mL).The filtrate was concentrated in vacuo, diluted with heptane/ tert-butyl methyl ether (5/1 , 20 mL) and the insoluble colourless solid was removed by filtration. The filtrate was purified by column chromatography on silica gel with heptane / EtOAc, 100/0 to 90/10. The crude product was filtered through a plug of NaHC03 (20g) and the filtrate evaporated in vacuo to give a golden oil (27.9 g). The oil was dissolved in heptanes (20 mL) and purified by filtered through a plug of silica gel (80 g), eluting with heptane to give 5-bromo-<strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> as a colourless oil (22.5g, 74% yield). 1 H-NMR (400 MHz, DMSO-d6, 298 K): delta ppm 4.03 (s, 3H) 7.95 (d, 1 H) 8.4 (d, 1 H).
74% With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; In trifluoroacetic acid; at 20℃; for 18h;Inert atmosphere; Intermediate 1 : 5-Bromo-<strong>[121643-44-5]2-methoxy-3-trifluoromethyl-pyridine</strong>To <strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> (20.0 g, 1 13.0 mmol) and 1 ,3-dibromo-5,5- dimethylimidazolidine-2,4-dione (43.6 g, 152.0 mmol) was added TFA (80 mL) and the resulting mixture stirred at rt for 18h under argon. The TFA was removed in vacuo (50 mbar, 45C) and the residue suspended in tert-butyl methyl ether (200 mL). The resulting colourless solid was removed by filtration and washed with tert-butyl methyl ether (50 mL). The filtrate was concentrated in vacuo and suspended in EtOAc (50 mL) The insoluble colourless solid was removed by filtration and washed with EtOAc (50 mL).The filtrate was concentrated in vacuo, diluted with heptane/ tert-butyl methyl ether (5/1 , 20 mL) and the insoluble colourless solid was removed by filtration. The filtrate was purified by column chromatography on silica gel with heptane / EtOAc, 100/0 to 90/10. The crude product was filtered through a plug of NaHC03 (20g) and the filtrate evaporated in vacuo to give a golden oil (27.9 g). The oil was dissolved in heptanes (20 mL) and purified by filtered through a plug of silica gel (80 g), eluting with heptane to give 5-bromo-<strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> as a colourless oil (22.5g, 74% yield). 1H-NMR (400 MHz, DMSO-d6, 298 K): delta ppm 4.03 (s, 3H) 7.95 (d, 1 H) 8.4 (d, 1 H).
74% With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; trifluoroacetic acid; at 20℃; for 18h;Inert atmosphere; To <strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> (20.0 g, 1 13.0 mmol) and 1 ,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (43.6 g, 152.0 mmol) was added TFA (80 ml_) and the resulting mixture stirred at rt for 8h under argon. The TFA was removed in vacuo (50 mbar, 45C) and the residue suspended in tert-butyl methyl ether (200 ml_). The resultingcolourless solid was removed by filtration and washed with tert-butyl methyl ether (50 mL). The filtrate was concentrated in vacuo and suspended in EtOAc (50 mL) The insoluble colourless solid was removed by filtration and washed with EtOAc (50 mL).The filtrate was concentrated in vacuo, diluted with heptane/ tert-butyl methyl ether (5/1 , 20 mL) and the insoluble colourless solid was removed by filtration. The filtrate was purified by column chromatography on silica gel with heptane / EtOAc, 100/0 to 90/10. The crude product was filtered through a plug of NaHC03 (20g) and the filtrate evaporated in vacuo to give a golden oil (27.9 g). The oil was dissolved in heptanes (20 mL) and purified by filtered through a plug of silica gel (80 g), eluting with heptane to give 5-bromo-<strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> as a colourless oil (22.5g, 74% yield).1H-NMR (400 MHz, DMSO-d6,298 K): delta ppm 4.03 (s, 3H) 7.95 (d, 1 H) 8.4 (d, 1 H).
74% With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; trifluoroacetic acid; at 20℃; for 18h;Inert atmosphere; Intermediate 1 5-Bromo-<strong>[121643-44-5]2-methoxy-3-trifluoromethyl-pyridine</strong> To <strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> (20.0 g, 113.0 mmol) and 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (43.6 g, 152.0 mmol) was added TFA (80 mL) and the resulting mixture stirred at rt for 18 h under argon. The TFA was removed in vacuo (50 mbar, 45 C.) and the residue suspended in tert-butyl methyl ether (200 mL). The resulting colourless solid was removed by filtration and washed with tert-butyl methyl ether (50 mL). The filtrate was concentrated in vacuo and suspended in EtOAc (50 mL) The insoluble colourless solid was removed by filtration and washed with EtOAc (50 mL). The filtrate was concentrated in vacuo, diluted with heptane/tert-butyl methyl ether (5/1, 20 mL) and the insoluble colourless solid was removed by filtration. The filtrate was purified by column chromatography on silica gel with heptane/EtOAc, 100/0 to 90/10. The crude product was filtered through a plug of NaHCO3 (20 g) and the filtrate evaporated in vacuo to give a golden oil (27.9 g). The oil was dissolved in heptanes (20 mL) and purified by filtered through a plug of silica gel (80 g), eluting with heptane to give 5-bromo-<strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> as a colourless oil (22.5 g, 74% yield). 1H-NMR (400 MHz, DMSO-d6, 298 K): delta ppm 4.03 (s, 3H) 7.95 (d, 1H) 8.4 (d, 1H).
52% With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; trifluoroacetic acid; at 20℃; for 16h; 2-Methoxy-3-trifluoromethyl-pyridine (2.7 g, 14.79 mmol) and 1 ,3-dibromo-5,5- dimethylhydantoin (5.28g, 18.48 mmol) were placed in a round-bottom flask. To this mixture was slowly added 40ml TFA. The mixture was stirred overnight at ambient temperature (16h). After completion of the reaction, TFA solvent was evaporated in vacuo and the resulting residue was neutralized to pH6-7 by the addition of saturated NaHC03. The aqueous layer was extracted with DCM two times and the combined extract was washed with brine, dried over magnesium sulfate and concentrated in vacuo to give a mixture of oil and white solid. The residue was redissolved into 20% Ethylacetate/Heptane (50ml) and the insoluble white solid was filtered off. The filtrate was concentrated and then purified by Flash- chromatography on silica gel (EtOAc/Heptane 5/95) to give 5-Bromo-2-methoxy-3- trifluoromethyl-pyridine as a colorless liquid (2.08 g, 52% yield).1 H-NMR (400 MHz, DMSO-d6, 298 K): ? ppm 4.03 (s, 3H) 7.95 (d, 1 H) 8.4 (d, 1 H).
9.4 g With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; trifluoroacetic acid; at 20℃; for 22h; Preparation Example 36 2-Methoxy-3-(trifluoromethyl)pyridine (8 g), 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (17 g), and trifluoroacetic acid (32 mL) were mixed, followed by stirring at room temperature for 22 hours. The reaction mixture was concentrated under reduced pressure, and to the residue was added diisopropyl ether. The precipitated solid was separated by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 5-bromo-<strong>[121643-44-5]2-methoxy-3-(trifluoromethyl)pyridine</strong> (9.4 g) as an oil.

 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1214377-42-0 ]

Fluorinated Building Blocks

Chemical Structure| 76041-79-7

A255665 [76041-79-7]

5-Bromo-3-(trifluoromethyl)pyridin-2-ol

Similarity: 0.93

Chemical Structure| 121643-44-5

A108112 [121643-44-5]

2-Methoxy-3-(trifluoromethyl)pyridine

Similarity: 0.88

Chemical Structure| 126728-58-3

A150155 [126728-58-3]

5-Bromo-2-(2,2,2-trifluoroethoxy)pyridine

Similarity: 0.76

Chemical Structure| 899452-26-7

A167321 [899452-26-7]

5-Bromo-2-(difluoromethoxy)pyridine

Similarity: 0.75

Chemical Structure| 219715-34-1

A580263 [219715-34-1]

2-Methoxy-4-(trifluoromethyl)pyridine

Similarity: 0.73

Bromides

Chemical Structure| 76041-79-7

A255665 [76041-79-7]

5-Bromo-3-(trifluoromethyl)pyridin-2-ol

Similarity: 0.93

Chemical Structure| 760207-87-2

A514770 [760207-87-2]

5-Bromo-2-methoxy-3-methylpyridine

Similarity: 0.82

Chemical Structure| 126728-58-3

A150155 [126728-58-3]

5-Bromo-2-(2,2,2-trifluoroethoxy)pyridine

Similarity: 0.76

Chemical Structure| 103058-87-3

A228768 [103058-87-3]

5-Bromo-2-methoxynicotinaldehyde

Similarity: 0.76

Chemical Structure| 899452-26-7

A167321 [899452-26-7]

5-Bromo-2-(difluoromethoxy)pyridine

Similarity: 0.75

Ethers

Chemical Structure| 121643-44-5

A108112 [121643-44-5]

2-Methoxy-3-(trifluoromethyl)pyridine

Similarity: 0.88

Chemical Structure| 760207-87-2

A514770 [760207-87-2]

5-Bromo-2-methoxy-3-methylpyridine

Similarity: 0.82

Chemical Structure| 126728-58-3

A150155 [126728-58-3]

5-Bromo-2-(2,2,2-trifluoroethoxy)pyridine

Similarity: 0.76

Chemical Structure| 103058-87-3

A228768 [103058-87-3]

5-Bromo-2-methoxynicotinaldehyde

Similarity: 0.76

Chemical Structure| 899452-26-7

A167321 [899452-26-7]

5-Bromo-2-(difluoromethoxy)pyridine

Similarity: 0.75

Trifluoromethyls

Chemical Structure| 76041-79-7

A255665 [76041-79-7]

5-Bromo-3-(trifluoromethyl)pyridin-2-ol

Similarity: 0.93

Chemical Structure| 121643-44-5

A108112 [121643-44-5]

2-Methoxy-3-(trifluoromethyl)pyridine

Similarity: 0.88

Chemical Structure| 126728-58-3

A150155 [126728-58-3]

5-Bromo-2-(2,2,2-trifluoroethoxy)pyridine

Similarity: 0.76

Chemical Structure| 219715-34-1

A580263 [219715-34-1]

2-Methoxy-4-(trifluoromethyl)pyridine

Similarity: 0.73

Chemical Structure| 1211532-15-8

A165392 [1211532-15-8]

6-Methoxy-5-(trifluoromethyl)nicotinic acid

Similarity: 0.73

Related Parent Nucleus of
[ 1214377-42-0 ]

Pyridines

Chemical Structure| 76041-79-7

A255665 [76041-79-7]

5-Bromo-3-(trifluoromethyl)pyridin-2-ol

Similarity: 0.93

Chemical Structure| 121643-44-5

A108112 [121643-44-5]

2-Methoxy-3-(trifluoromethyl)pyridine

Similarity: 0.88

Chemical Structure| 760207-87-2

A514770 [760207-87-2]

5-Bromo-2-methoxy-3-methylpyridine

Similarity: 0.82

Chemical Structure| 126728-58-3

A150155 [126728-58-3]

5-Bromo-2-(2,2,2-trifluoroethoxy)pyridine

Similarity: 0.76

Chemical Structure| 103058-87-3

A228768 [103058-87-3]

5-Bromo-2-methoxynicotinaldehyde

Similarity: 0.76